BioSym raises $150M Series C and launches generative drug-discovery model

AI · 5 min read

The Series C was led by Biotech Horizons and strategic pharma investors, aimed at scaling preclinical pipelines and expanding wet-lab partnerships. BioSym plans to deploy the capital to validate multiple therapeutic programs that originated from its generative platform.

BioSym's new suite couples generative chemistry with property prediction and synthesis-aware suggestions, allowing discovery teams to iterate on candidate molecules with a clearer path to manufacturability. The company added model interpretability features to help chemists understand substructure contributions to predicted properties.

BioSym will offer the suite under a collaborative research model, combining licensed compute with in-house validation labs. The company cites accelerated hit-to-lead times in initial programs and expects the funding to push multiple candidates toward IND-enabling studies.